EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prolactin and thyrotropin response to trh in premenopausal women with fibrocystic disease of the breast



Prolactin and thyrotropin response to trh in premenopausal women with fibrocystic disease of the breast



Hormone Research (Basel) 21(3): 137-144



Plasma PRL [prolactin], TSH, total and free T4 [thyroxine] total and free T3 [triiodothyronine] and 17.beta.-estradiol were evaluated in 29 premenopausal women with well-documented fibrocystic disease of the breast and in 29 healthy matched controls. Plasma PRL and TSH dynamics after acute TRH injection (200 .mu.g i.v.) were also determined. All hormonal measurements were performed in the follicular phase of the menstrual cycle. Neither patients nor controls showed any thyroid function impairment. Basal plasma levels of the estimated hormones were in the normal range in both groups. When considering data pertinent to PRL and TSH secretory patterns after TRH stimulation, no difference was recorded between patients and controls for TSH secretion, evaluated in terms of maximum peak, net (.DELTA.) and percent (.DELTA.%) increase above the baseline level and integrated area of response. The response of PRL was significantly higher in patients than controls (maximum peak at 20 min, mean .+-. SE, 119.9 .+-. 14.1 vs. 60.8 .+-. 5.5 ng/ml; P < 0.001; integrated area of response, 5725 .+-. 908 vs. 3243 .+-. 266 ng/ml/120 min, P < 0.01). The results are compatible with the view that, in most patients with fibrocystic disease of the breast, there are abnormalities in the control of PRL secretion, which led to enhanced release of the hormone after stimulation. In such cases the control of TSH appears to be operating normally.

(PDF emailed within 1 workday: $29.90)

Accession: 006198251

Download citation: RISBibTeXText



Related references

Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. Hormone Research 21(3): 137-144, 1985

Release of prolactin thyrotropin and growth hormone in women with cyclical mastalgia and fibrocystic disease of the breast. Cancer 56(3): 500-502, 1985

Fibrocystic disease of the breast in premenopausal women histohormonal correlation and response to lhrh analog treatment. American Journal of Obstetrics & Gynecology 164(5 PART 1): 1181-1189, 1991

Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. American Journal of Obstetrics and Gynecology 164(5 Pt 1): 1181-1189, 1991

Prolactin dynamics after acute stimulation with trh and domperidone in women with fibrocystic disease of the breast. Angeli, A. Bradlow And L. Dogliotti (ed.). Annals Of The New York Academy Of Sciences, Vol. 464. Endocrinology Of The Breast: Basic And Clinical Aspects; International Congress, Turin, Italy, Sept. 2, 1984. Xvi 640p. The New York Academy Of Sciences: New York, N.y., Usa. Illus. 589-591, 1986

Molecular heterogeneity of serum prolactin in women with fibrocystic disease and breast cancer. Journal of Gynaecological Endocrinology 2(1-2): 11-16, 1986

Effect of sulpiride on the secretion of prolactin and somatotropic hormone in premenopausal women affected by fibrocystic mastopathy. Chirurgia E Patologia Sperimentale 31(2): 59-68, 1983

Serum and breast duct fluid prolactin and estrogen levels in healthy Finnish and American women and patients with fibrocystic disease. Cancer 57(8): 1550-1554, 1986

Breast tissue and breast duct fluid dhas concentrations in premenopausal mammary cancer and fibrocystic disease. Castagnetta, L , Et Al (Ed ) Annals Of The New York Academy Of Sciences, Vol 595 Steroid Formation, Degradation, And Action in Peripheral Tissues; First International Symposium, Taormina, Italy, March 14-18, 1989 Xiii+489p New York Academy Of Sciences: New York, New York, Usa Illus 467-472, 1990

The concentrations of prolactin and estrogens in women with fibrocystic changes in the breast. Ginekologia Polska 73(7): 594-599, 2002

The role of estrogen in the TSH and prolactin responses to thyrotropin-releasing hormone in postmenopausal as compared to premenopausal women. Hormone and Metabolic Research 24(11): 528-531, 1992

Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53(6): 1311-1315, 1984

Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer 68(6): 1401-1405, 1991

Effect of acute increases in serum tri iodo thyronine on thyrotropin and prolactin response to thyrotropin releasing hormone and estimates of pituitary stores of thyrotropin and prolactin in normal subjects and in patients with primary hypo thyroidism. Journal of Clinical Endocrinology & Metabolism 42(3): 443-458, 1976

Serum prolactin levels in patients with fibrocystic breast disease. Obstetrics and Gynecology 64(3): 381-385, 1984